TY - STD TI - The European Cardiovascular Magnetic Resonance Registry.www.eurocmr-registry.com, UR - http://www.eurocmr-registry.com ID - ref1 ER - TY - JOUR AU - Cowper, S. E. PY - 2001 DA - 2001// TI - Nephrogenic fibrosing dermopathy JO - Am J Dermatopathol VL - 23 UR - https://doi.org/10.1097/00000372-200110000-00001 DO - 10.1097/00000372-200110000-00001 ID - Cowper2001 ER - TY - JOUR AU - Grobner, T. AU - Prischl, F. C. PY - 2007 DA - 2007// TI - Gadolinium and nephrogenic systemic fibrosis JO - Kidney Int VL - 72 UR - https://doi.org/10.1038/sj.ki.5002338 DO - 10.1038/sj.ki.5002338 ID - Grobner2007 ER - TY - JOUR AU - Idee, J. M. PY - 2008 DA - 2008// TI - Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review JO - Toxicology VL - 248 UR - https://doi.org/10.1016/j.tox.2008.03.012 DO - 10.1016/j.tox.2008.03.012 ID - Idee2008 ER - TY - JOUR AU - Marckmann, P. PY - 2006 DA - 2006// TI - Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging JO - J Am Soc Nephrol VL - 17 UR - https://doi.org/10.1681/ASN.2006060601 DO - 10.1681/ASN.2006060601 ID - Marckmann2006 ER - TY - JOUR AU - Morcos, S. K. PY - 2006 DA - 2006// TI - Gadolinium-based contrast agents and nephrotoxicity JO - Catheter Cardiovasc Interv VL - 68 UR - https://doi.org/10.1002/ccd.20929 DO - 10.1002/ccd.20929 ID - Morcos2006 ER - TY - JOUR AU - Thomsen, H. S. AU - Morcos, S. K. AU - Dawson, P. PY - 2006 DA - 2006// TI - Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? JO - Clin Radiol VL - 61 UR - https://doi.org/10.1016/j.crad.2006.09.003 DO - 10.1016/j.crad.2006.09.003 ID - Thomsen2006 ER - TY - STD TI - NSF Registry.www.pathmax.com/dermweb, UR - http://www.pathmax.com/dermweb ID - ref8 ER - TY - JOUR AU - Martin, D. R. PY - 2010 DA - 2010// TI - Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols JO - J Magn Reson Imaging VL - 31 UR - https://doi.org/10.1002/jmri.22024 DO - 10.1002/jmri.22024 ID - Martin2010 ER - TY - JOUR AU - Rees, O. AU - Agarwal, S. K. PY - 2010 DA - 2010// TI - Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media JO - Clin Radiol VL - 65 UR - https://doi.org/10.1016/j.crad.2010.04.012 DO - 10.1016/j.crad.2010.04.012 ID - Rees2010 ER - TY - JOUR AU - Wang, Y. PY - 2011 DA - 2011// TI - Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines JO - Radiology VL - 260 UR - https://doi.org/10.1148/radiol.11102340 DO - 10.1148/radiol.11102340 ID - Wang2011 ER - TY - JOUR AU - Caravan, P. PY - 2001 DA - 2001// TI - Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging JO - Inorg Chem VL - 40 UR - https://doi.org/10.1021/ic001117r DO - 10.1021/ic001117r ID - Caravan2001 ER - TY - BOOK PY - 2002 DA - 2002// TI - Extracellular MRI Contrast Agents Based on Gadolinium Contrast Agents PB - Springer Berlin CY - Heidelberg ID - ref13 ER - TY - JOUR AU - Hermann, P. PY - 2008 DA - 2008// TI - Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes JO - Dalton Trans VL - 23 UR - https://doi.org/10.1039/b719704g DO - 10.1039/b719704g ID - Hermann2008 ER - TY - JOUR AU - Brücher, E. PY - 2002 DA - 2002// TI - Kinetic Stabilities of Gadolinium(III) Chelates Used as MRI Contrast Agents JO - Top Curr Chem VL - 221 UR - https://doi.org/10.1007/3-540-45733-X_4 DO - 10.1007/3-540-45733-X_4 ID - Brücher2002 ER - TY - JOUR AU - Aime, S. AU - Caravan, P. PY - 2009 DA - 2009// TI - Biodistribution of gadolinium-based contrast agents, including gadolinium deposition JO - J Magn Reson Imaging VL - 30 UR - https://doi.org/10.1002/jmri.21969 DO - 10.1002/jmri.21969 ID - Aime2009 ER - TY - JOUR AU - Ersoy, H. AU - Rybicki, F. J. PY - 2007 DA - 2007// TI - Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis JO - J Magn Reson Imaging VL - 26 UR - https://doi.org/10.1002/jmri.21135 DO - 10.1002/jmri.21135 ID - Ersoy2007 ER - TY - JOUR AU - Frenzel, T. PY - 2008 DA - 2008// TI - Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C JO - Invest Radiol VL - 43 UR - https://doi.org/10.1097/RLI.0b013e3181852171 DO - 10.1097/RLI.0b013e3181852171 ID - Frenzel2008 ER - TY - JOUR AU - Idee, J. M. PY - 2009 DA - 2009// TI - Role of thermodynamic and kinetic parameters in gadolinium chelate stability JO - J Magn Reson Imaging VL - 30 UR - https://doi.org/10.1002/jmri.21967 DO - 10.1002/jmri.21967 ID - Idee2009 ER - TY - JOUR AU - Wedeking, P. AU - Kumar, K. AU - Tweedle, M. F. PY - 1992 DA - 1992// TI - Dissociation of gadolinium chelates in mice: relationship to chemical characteristics JO - Magn Reson Imaging VL - 10 UR - https://doi.org/10.1016/0730-725X(92)90016-S DO - 10.1016/0730-725X(92)90016-S ID - Wedeking1992 ER - TY - JOUR AU - Port, M. PY - 2008 DA - 2008// TI - Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review JO - Biometals VL - 21 UR - https://doi.org/10.1007/s10534-008-9135-x DO - 10.1007/s10534-008-9135-x ID - Port2008 ER - TY - JOUR AU - Prince, M. R. PY - 2011 DA - 2011// TI - Incidence of Immediate Gadolinium Contrast Media Reactions JO - Am J Roentgenol VL - 196 UR - https://doi.org/10.2214/AJR.10.4885 DO - 10.2214/AJR.10.4885 ID - Prince2011 ER - TY - JOUR AU - Joffe, P. AU - Thomsen, H. S. AU - Meusel, M. PY - 1998 DA - 1998// TI - Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis JO - Acad Radiol VL - 5 UR - https://doi.org/10.1016/S1076-6332(98)80191-8 DO - 10.1016/S1076-6332(98)80191-8 ID - Joffe1998 ER - TY - CHAP AU - Frenzel PY - 2008 DA - 2008// BT - Stability of Gadolinium- based magnetic resonance imaging contrast agents in human serum at 37°C ID - Frenzel2008 ER - TY - JOUR AU - Cacheris, W. P. AU - Quay, S. C. AU - Rocklage, S. M. PY - 1990 DA - 1990// TI - The relationship between thermodynamics and the toxicity of gadolinium complexes JO - Magn Reson Imaging VL - 8 UR - https://doi.org/10.1016/0730-725X(90)90055-7 DO - 10.1016/0730-725X(90)90055-7 ID - Cacheris1990 ER - TY - JOUR AU - Imura, H. AU - Choppin, G. R. AU - Cacheris, W. P. AU - de Learie, L. A. AU - Dunn, T. J. AU - White, D. H. PY - 1997 DA - 1997// TI - Thermodynamics and NMR studies of DTPA-bis(methoxyethylamide) and its derivatives. Protonation and complexation with Ln(III) JO - Inorganica Chimica Acta VL - 258 UR - https://doi.org/10.1016/S0020-1693(96)05522-3 DO - 10.1016/S0020-1693(96)05522-3 ID - Imura1997 ER - TY - JOUR AU - Kumar, R. PY - 1994 DA - 1994// TI - Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs to 3'-azido-3'-deoxythymidine (AZT) JO - J Med Chem VL - 37 UR - https://doi.org/10.1021/jm00051a006 DO - 10.1021/jm00051a006 ID - Kumar1994 ER - TY - JOUR AU - Moreau, J. PY - 2004 DA - 2004// TI - Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS JO - Chemistry VL - 10 UR - https://doi.org/10.1002/chem.200400006 DO - 10.1002/chem.200400006 ID - Moreau2004 ER - TY - JOUR AU - Schmitt-Willich, H. PY - 1999 DA - 1999// TI - Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA JO - Inorg Chem VL - 38 UR - https://doi.org/10.1021/ic981072i DO - 10.1021/ic981072i ID - Schmitt-Willich1999 ER - TY - JOUR AU - Toth, E. AU - Kiraly, R. AU - Platzek, J. AU - Raduchel, B. AU - Brucher, E. PY - 1996 DA - 1996// TI - Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate JO - Inorganica Chimica Acta VL - 249 UR - https://doi.org/10.1016/0020-1693(96)05094-3 DO - 10.1016/0020-1693(96)05094-3 ID - Toth1996 ER - TY - JOUR AU - Uggeri, F. AU - Uggeri, F. A. S. AU - Anelli, P. AU - Botta, M. AU - Brocchetta, M. AU - De Haen, C. AU - Ermondi, G. AU - Grandi, M. AU - Paoli, P. PY - 1995 DA - 1995// TI - Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln=Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)]gadolinate(2-) in a mixture with its enantiomer JO - Inorg Chem VL - 34 UR - https://doi.org/10.1021/ic00107a017 DO - 10.1021/ic00107a017 ID - Uggeri1995 ER - TY - JOUR AU - Haylor, J. PY - 2010 DA - 2010// TI - Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat JO - Invest Radiol VL - 45 UR - https://doi.org/10.1097/RLI.0b013e3181eb51f2 DO - 10.1097/RLI.0b013e3181eb51f2 ID - Haylor2010 ER - TY - JOUR AU - Sadowski, E. A. PY - 2007 DA - 2007// TI - Nephrogenic systemic fibrosis: risk factors and incidence estimation JO - Radiology VL - 243 UR - https://doi.org/10.1148/radiol.2431062144 DO - 10.1148/radiol.2431062144 ID - Sadowski2007 ER - TY - JOUR AU - Kuo, P. H. PY - 2007 DA - 2007// TI - Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis JO - Radiology VL - 242 UR - https://doi.org/10.1148/radiol.2423061640 DO - 10.1148/radiol.2423061640 ID - Kuo2007 ER - TY - JOUR AU - Edward, M. PY - 2010 DA - 2010// TI - Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation JO - Radiology VL - 256 UR - https://doi.org/10.1148/radiol.10091131 DO - 10.1148/radiol.10091131 ID - Edward2010 ER - TY - JOUR AU - Morcos, S. K. PY - 2011 DA - 2011// TI - Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? JO - Eur Radiol VL - 21 UR - https://doi.org/10.1007/s00330-010-1951-z DO - 10.1007/s00330-010-1951-z ID - Morcos2011 ER - TY - JOUR AU - Tweedle, M. F. AU - Wedeking, P. AU - Kumar, K. PY - 1995 DA - 1995// TI - Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats JO - Invest Radiol VL - 30 UR - https://doi.org/10.1097/00004424-199506000-00008 DO - 10.1097/00004424-199506000-00008 ID - Tweedle1995 ER - TY - JOUR AU - Varani, J. PY - 2009 DA - 2009// TI - Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts JO - Invest Radiol VL - 44 UR - https://doi.org/10.1097/RLI.0b013e31818f76b5 DO - 10.1097/RLI.0b013e31818f76b5 ID - Varani2009 ER - TY - JOUR AU - High, W. A. AU - Ayers, R. A. AU - Cowper, S. E. PY - 2007 DA - 2007// TI - Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis JO - J Am Acad Dermatol VL - 56 UR - https://doi.org/10.1016/j.jaad.2007.01.022 DO - 10.1016/j.jaad.2007.01.022 ID - High2007 ER - TY - JOUR AU - High, W. A. PY - 2007 DA - 2007// TI - Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis JO - J Am Acad Dermatol VL - 56 UR - https://doi.org/10.1016/j.jaad.2006.10.047 DO - 10.1016/j.jaad.2006.10.047 ID - High2007 ER - TY - JOUR AU - Mendoza, F. A. PY - 2006 DA - 2006// TI - Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature JO - Semin Arthritis Rheum VL - 35 UR - https://doi.org/10.1016/j.semarthrit.2005.08.002 DO - 10.1016/j.semarthrit.2005.08.002 ID - Mendoza2006 ER - TY - JOUR AU - Quatresooz, P. PY - 2010 DA - 2010// TI - Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis JO - Appl Immunohistochem Mol Morphol VL - 18 ID - Quatresooz2010 ER - TY - JOUR AU - Bhagavathula, N. PY - 2010 DA - 2010// TI - Fibroblast response to gadolinium: role for platelet-derived growth factor receptor JO - Invest Radiol VL - 45 UR - https://doi.org/10.1097/RLI.0b013e3181e943d2 DO - 10.1097/RLI.0b013e3181e943d2 ID - Bhagavathula2010 ER - TY - JOUR AU - Gambichler, T. PY - 2009 DA - 2009// TI - Decorin is significantly overexpressed in nephrogenic systemic fibrosis JO - Am J Clin Pathol VL - 132 UR - https://doi.org/10.1309/AJCPGB55YDURJXZC DO - 10.1309/AJCPGB55YDURJXZC ID - Gambichler2009 ER - TY - JOUR AU - Pietsch, H. PY - 2011 DA - 2011// TI - The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats JO - Invest Radiol VL - 46 UR - https://doi.org/10.1097/RLI.0b013e3181efd49a DO - 10.1097/RLI.0b013e3181efd49a ID - Pietsch2011 ER - TY - JOUR AU - Piera-Velazquez, S. PY - 2010 DA - 2010// TI - Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2009.127761 DO - 10.1136/ard.2009.127761 ID - Piera-Velazquez2010 ER - TY - JOUR AU - Kelly, B. C. PY - 2010 DA - 2010// TI - The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis JO - J Am Acad Dermatol VL - 63 UR - https://doi.org/10.1016/j.jaad.2009.09.006 DO - 10.1016/j.jaad.2009.09.006 ID - Kelly2010 ER - TY - JOUR AU - Del Galdo, F. PY - 2010 DA - 2010// TI - NFkappaB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2010.134858 DO - 10.1136/ard.2010.134858 ID - Del Galdo2010 ER - TY - JOUR AU - Wiesinger, B. PY - 2011 DA - 2011// TI - Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis JO - Invest Radiol VL - 46 UR - https://doi.org/10.1097/RLI.0b013e31820218e9 DO - 10.1097/RLI.0b013e31820218e9 ID - Wiesinger2011 ER - TY - JOUR AU - Golding, L. P. AU - Provenzale, J. M. PY - 2008 DA - 2008// TI - Nephrogenic systemic fibrosis: possible association with a predisposing infection JO - AJR Am J Roentgenol VL - 190 UR - https://doi.org/10.2214/AJR.07.2884 DO - 10.2214/AJR.07.2884 ID - Golding2008 ER - TY - JOUR AU - Yildiz, S. PY - 2011 DA - 2011// TI - Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level JO - Clin Biochem VL - 44 UR - https://doi.org/10.1016/j.clinbiochem.2011.05.005 DO - 10.1016/j.clinbiochem.2011.05.005 ID - Yildiz2011 ER - TY - JOUR AU - Hope, T. A. PY - 2009 DA - 2009// TI - Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron JO - Radiology VL - 253 UR - https://doi.org/10.1148/radiol.2532090580 DO - 10.1148/radiol.2532090580 ID - Hope2009 ER - TY - JOUR AU - Schieren, G. PY - 2010 DA - 2010// TI - Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions JO - Am J Kidney Dis VL - 55 UR - https://doi.org/10.1053/j.ajkd.2010.01.021 DO - 10.1053/j.ajkd.2010.01.021 ID - Schieren2010 ER - TY - JOUR AU - Vakil, V. PY - 2009 DA - 2009// TI - Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation JO - J Magn Reson Imaging VL - 30 UR - https://doi.org/10.1002/jmri.21800 DO - 10.1002/jmri.21800 ID - Vakil2009 ER - TY - JOUR AU - Gou, B. D. PY - 2010 DA - 2010// TI - Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages JO - Toxicol In Vitro VL - 24 UR - https://doi.org/10.1016/j.tiv.2010.05.004 DO - 10.1016/j.tiv.2010.05.004 ID - Gou2010 ER - TY - JOUR AU - Cowper, S. E. AU - Rabach, M. AU - Girardi, M. PY - 2008 DA - 2008// TI - Clinical and histological findings in nephrogenic systemic fibrosis JO - Eur J Radiol VL - 66 UR - https://doi.org/10.1016/j.ejrad.2008.01.016 DO - 10.1016/j.ejrad.2008.01.016 ID - Cowper2008 ER - TY - STD TI - NSF Registry, updated. 2011,www.icnfdr.org, UR - http://www.icnfdr.org ID - ref57 ER - TY - JOUR AU - Cowper, S. E. PY - 2003 DA - 2003// TI - Nephrogenic fibrosing dermopathy: the first 6 years JO - Curr Opin Rheumatol VL - 15 UR - https://doi.org/10.1097/00002281-200311000-00017 DO - 10.1097/00002281-200311000-00017 ID - Cowper2003 ER - TY - JOUR AU - Samtleben, W. PY - 2007 DA - 2007// TI - Nephrogenic systemic fibrosis JO - Radiologe VL - 47 UR - https://doi.org/10.1007/s00117-007-1545-1 DO - 10.1007/s00117-007-1545-1 ID - Samtleben2007 ER - TY - JOUR AU - Cowper, S. E. PY - 2008 DA - 2008// TI - Nephrogenic systemic fibrosis: an overview JO - J Am Coll Radiol VL - 5 UR - https://doi.org/10.1016/j.jacr.2007.08.013 DO - 10.1016/j.jacr.2007.08.013 ID - Cowper2008 ER - TY - JOUR AU - Steen, H. PY - 2009 DA - 2009// TI - Acute phase reaction to gadolinium-DTPA in dialysis patients JO - Nephrol Dial Transplant VL - 24 UR - https://doi.org/10.1093/ndt/gfn655 DO - 10.1093/ndt/gfn655 ID - Steen2009 ER - TY - JOUR AU - Brockow, K. AU - Ring, J. PY - 2011 DA - 2011// TI - Anaphylaxis to radiographic contrast media JO - Curr Opin Allergy Clin Immunol VL - 11 UR - https://doi.org/10.1097/ACI.0b013e32834877c3 DO - 10.1097/ACI.0b013e32834877c3 ID - Brockow2011 ER - TY - JOUR AU - Prince, M. R. PY - 2009 DA - 2009// TI - Risk factors for NSF: a literature review JO - J Magn Reson Imaging VL - 30 UR - https://doi.org/10.1002/jmri.21973 DO - 10.1002/jmri.21973 ID - Prince2009 ER - TY - JOUR AU - Prince, M. R. AU - Arnoldus, C. AU - Frisoli, J. K. PY - 1996 DA - 1996// TI - Nephrotoxicity of high-dose gadolinium compared with iodinated contrast JO - J Magn Reson Imaging VL - 6 UR - https://doi.org/10.1002/jmri.1880060129 DO - 10.1002/jmri.1880060129 ID - Prince1996 ER - TY - JOUR AU - Prince, M. R. PY - 2008 DA - 2008// TI - Incidence of nephrogenic systemic fibrosis at two large medical centers JO - Radiology VL - 248 UR - https://doi.org/10.1148/radiol.2483071863 DO - 10.1148/radiol.2483071863 ID - Prince2008 ER - TY - JOUR AU - Deo, A. AU - Fogel, M. AU - Cowper, S. E. PY - 2007 DA - 2007// TI - Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure JO - Clin J Am Soc Nephrol VL - 2 UR - https://doi.org/10.2215/CJN.03921106 DO - 10.2215/CJN.03921106 ID - Deo2007 ER - TY - JOUR AU - Collidge, T. A. PY - 2007 DA - 2007// TI - Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort JO - Radiology VL - 245 UR - https://doi.org/10.1148/radiol.2451070353 DO - 10.1148/radiol.2451070353 ID - Collidge2007 ER - TY - JOUR AU - Kallen, A. J. PY - 2008 DA - 2008// TI - Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case–control study JO - Am J Kidney Dis VL - 51 UR - https://doi.org/10.1053/j.ajkd.2007.12.036 DO - 10.1053/j.ajkd.2007.12.036 ID - Kallen2008 ER - TY - JOUR AU - Marckmann, P. PY - 2007 DA - 2007// TI - Case–control study of gadodiamide-related nephrogenic systemic fibrosis JO - Nephrol Dial Transplant VL - 22 UR - https://doi.org/10.1093/ndt/gfm261 DO - 10.1093/ndt/gfm261 ID - Marckmann2007 ER - TY - STD TI - FDA - GBCA and NSF Core Presentations: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196218.pdf. As seen on 1.Februar 2012 UR - http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196218.pdf ID - ref70 ER - TY - JOUR AU - Zou, Z. AU - Ma, L. PY - 2011 DA - 2011// TI - Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases JO - Indian J Dermatol VL - 56 UR - https://doi.org/10.4103/0019-5154.77556 DO - 10.4103/0019-5154.77556 ID - Zou2011 ER - TY - JOUR AU - Auron, A. AU - Shao, L. AU - Warady, B. A. PY - 2006 DA - 2006// TI - Nephrogenic fibrosing dermopathy in children JO - Pediatr Nephrol VL - 21 UR - https://doi.org/10.1007/s00467-006-0174-7 DO - 10.1007/s00467-006-0174-7 ID - Auron2006 ER - TY - JOUR AU - Foss, C. PY - 2009 DA - 2009// TI - Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy JO - Pediatr Dermatol VL - 26 UR - https://doi.org/10.1111/j.1525-1470.2008.00802.x DO - 10.1111/j.1525-1470.2008.00802.x ID - Foss2009 ER - TY - JOUR AU - Jain, S. M. PY - 2004 DA - 2004// TI - Nephrogenic fibrosing dermopathy in pediatric patients JO - Pediatr Nephrol VL - 19 UR - https://doi.org/10.1007/s00467-003-1380-1 DO - 10.1007/s00467-003-1380-1 ID - Jain2004 ER - TY - JOUR AU - Marckmann, P. PY - 2008 DA - 2008// TI - An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital JO - Eur J Radiol VL - 66 UR - https://doi.org/10.1016/j.ejrad.2008.01.032 DO - 10.1016/j.ejrad.2008.01.032 ID - Marckmann2008 ER - TY - JOUR AU - Silberzweig, J. I. AU - Chung, M. PY - 2009 DA - 2009// TI - Removal of gadolinium by dialysis: review of different strategies and techniques JO - J Magn Reson Imaging VL - 30 UR - https://doi.org/10.1002/jmri.21981 DO - 10.1002/jmri.21981 ID - Silberzweig2009 ER - TY - JOUR AU - Chung, H. J. AU - Chung, K. Y. PY - 2004 DA - 2004// TI - Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin JO - Br J Dermatol VL - 150 UR - https://doi.org/10.1111/j.1365-2133.2003.05795.x DO - 10.1111/j.1365-2133.2003.05795.x ID - Chung2004 ER - TY - JOUR AU - Duffy, K. L. PY - 2008 DA - 2008// TI - Treatment of nephrogenic systemic fibrosis with Re-PUVA JO - J Am Acad Dermatol VL - 59 UR - https://doi.org/10.1016/j.jaad.2007.08.035 DO - 10.1016/j.jaad.2007.08.035 ID - Duffy2008 ER - TY - JOUR AU - Fretellier, N. PY - 2011 DA - 2011// TI - Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis JO - Invest Radiol VL - 46 UR - https://doi.org/10.1097/RLI.0b013e3181f54044 DO - 10.1097/RLI.0b013e3181f54044 ID - Fretellier2011 ER - TY - JOUR AU - Geara, A. S. AU - El-Imad, B. AU - El-Sayegh, S. PY - 2010 DA - 2010// TI - Acetazolamide therapy in meningeal involvement of nephrogenic systemic fibrosis JO - Intern Med J VL - 40 UR - https://doi.org/10.1111/j.1445-5994.2010.02378.x DO - 10.1111/j.1445-5994.2010.02378.x ID - Geara2010 ER - TY - JOUR AU - Kay, J. AU - High, W. A. PY - 2008 DA - 2008// TI - Imatinib mesylate treatment of nephrogenic systemic fibrosis JO - Arthritis Rheum VL - 58 UR - https://doi.org/10.1002/art.23696 DO - 10.1002/art.23696 ID - Kay2008 ER - TY - JOUR AU - Marckmann, P. AU - Nielsen, A. H. AU - Sloth, J. J. PY - 2008 DA - 2008// TI - Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3–5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis JO - Nephrol Dial Transplant VL - 23 UR - https://doi.org/10.1093/ndt/gfn217 DO - 10.1093/ndt/gfn217 ID - Marckmann2008 ER - TY - JOUR AU - Mathur, K. PY - 2008 DA - 2008// TI - Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature JO - J Clin Apher VL - 23 UR - https://doi.org/10.1002/jca.20170 DO - 10.1002/jca.20170 ID - Mathur2008 ER - TY - JOUR AU - Panesar, M. PY - 2010 DA - 2010// TI - Transmetallation and gadolinium: Do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients? JO - Hemodialysis Int VL - 14 UR - https://doi.org/10.1111/j.1542-4758.2010.00456.x DO - 10.1111/j.1542-4758.2010.00456.x ID - Panesar2010 ER - TY - JOUR AU - Perazella, M. A. AU - Reilly, R. F. PY - 2011 DA - 2011// TI - Imaging patients with kidney disease: how do we approach contrast-related toxicity? JO - Am J Med Sci VL - 341 UR - https://doi.org/10.1097/MAJ.0b013e3181f016e6 DO - 10.1097/MAJ.0b013e3181f016e6 ID - Perazella2011 ER - TY - JOUR AU - Pieringer, H. PY - 2007 DA - 2007// TI - Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis JO - Nephrol Dial Transplant VL - 22 UR - https://doi.org/10.1093/ndt/gfm435 DO - 10.1093/ndt/gfm435 ID - Pieringer2007 ER - TY - JOUR AU - Richmond, H. PY - 2007 DA - 2007// TI - Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis JO - Arch Dermatol VL - 143 UR - https://doi.org/10.1001/archderm.143.8.1025 DO - 10.1001/archderm.143.8.1025 ID - Richmond2007 ER - TY - JOUR AU - Swaminathan, S. PY - 2010 DA - 2010// TI - Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase JO - J Am Acad Dermatol VL - 62 UR - https://doi.org/10.1016/j.jaad.2009.04.022 DO - 10.1016/j.jaad.2009.04.022 ID - Swaminathan2010 ER - TY - JOUR AU - Tran, K. T. PY - 2009 DA - 2009// TI - UV-A1 therapy for nephrogenic systemic fibrosis JO - Arch Dermatol VL - 145 UR - https://doi.org/10.1001/archdermatol.2009.245 DO - 10.1001/archdermatol.2009.245 ID - Tran2009 ER - TY - STD TI - U.S. Food and Drug Administration: .www.fda.org,%20section%20drugs/drug%20safety, UR - http://www.fda.org/%20section%20drugs/drug%20safety ID - ref90 ER - TY - JOUR AU - Levey, A. S. PY - 2003 DA - 2003// TI - National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification JO - Ann Intern Med VL - 139 UR - https://doi.org/10.7326/0003-4819-139-2-200307150-00013 DO - 10.7326/0003-4819-139-2-200307150-00013 ID - Levey2003 ER - TY - BOOK PY - 2010 DA - 2010// TI - Hauptinformationen für Bedienstete im Gesundheitswesen - Gadolinium- haltige Kontrastmittel und das Risiko für das Auftreten von nephrogenen systemischen Fibrosen (NSF) ID - ref92 ER - TY - STD TI - European Medicines Agency: www.ema.europa.eu/ema/, key words: Gadolinium based contrast agents UR - http://www.ema.europa.eu/ema/ ID - ref93 ER - TY - STD TI - European Society of Urogenial Radiology, ESUR: . 2010,www.esur.org, UR - http://www.esur.org ID - ref94 ER - TY - JOUR AU - De Campos, R. O. P. PY - 2011 DA - 2011// TI - Quarter-Dose (0.025 mmol/kg) Gadobenate Dimeglumine for Abdominal MRI in Patients at Risk for Nephrogenic Systemic Fibrosis: Preliminary Observations JO - Am J Roentgenol VL - 196 UR - https://doi.org/10.2214/AJR.10.4500 DO - 10.2214/AJR.10.4500 ID - De Campos2011 ER - TY - JOUR AU - Costelloe, C. M. PY - 2011 DA - 2011// TI - Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors JO - Skeletal Radiol VL - 40 UR - https://doi.org/10.1007/s00256-010-1028-8 DO - 10.1007/s00256-010-1028-8 ID - Costelloe2011 ER - TY - JOUR AU - Anzidei, M. PY - 2011 DA - 2011// TI - Low-dose contrast-enhanced time-resolved MR angiography at 3 T: diagnostic accuracy for treatment planning and follow-up of vascular malformations JO - Clin Radiol VL - 66 UR - https://doi.org/10.1016/j.crad.2011.08.003 DO - 10.1016/j.crad.2011.08.003 ID - Anzidei2011 ER - TY - JOUR AU - Nael, K. AU - Moriarty, J. M. AU - Finn, J. P. PY - 2011 DA - 2011// TI - Low dose CE-MRA JO - Eur J Radiol VL - 80 UR - https://doi.org/10.1016/j.ejrad.2011.01.092 DO - 10.1016/j.ejrad.2011.01.092 ID - Nael2011 ER - TY - BOOK PY - 2010 DA - 2010// TI - Subcommittee on MR Safety: ACR Manual on Contrast Media, Version 7 ID - ref99 ER - TY - JOUR AU - Kramer, C. M. PY - 2008 DA - 2008// TI - Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols JO - J Cardiovasc Magn Reson VL - 10 UR - https://doi.org/10.1186/1532-429X-10-35 DO - 10.1186/1532-429X-10-35 ID - Kramer2008 ER - TY - JOUR AU - Ishida, M. PY - 2011 DA - 2011// TI - Development of a universal dual-bolus injection scheme for the quantitative assessment of myocardial perfusion cardiovascular magnetic resonance JO - J Cardiovasc Magn Reson VL - 13 UR - https://doi.org/10.1186/1532-429X-13-28 DO - 10.1186/1532-429X-13-28 ID - Ishida2011 ER - TY - STD TI - Informatin on drugs to be found on www.fda.org(US Food and Drug administration), http://www.drugs.com/pro/vasovist.html(Drug Information Online), www.medicines.org.au/files/aspdotar.pdf (Medicines Information Australia); http://www.primovist.com/scripts/pages/en/primovist/index.php (Bayer Product Information); http://www.gadovist.ch/de/gadovist/dosierung-anwendung/(Bayer Product Information) UR - http://www.gadovist.ch/de/gadovist/dosierung-anwendung/ ID - ref102 ER -